All the news Showing 9 of 9 articles from: Adherence to treatmentGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Ultra-short course treatment for hepatitis C: high failure rate but does not compromise second-line treatment Keith Alcorn / 13 September 2021 Ultra-short treatment courses tailored to a person's pre-treatment viral load deliver lower cure rates than 8-week treatment courses, but failure of ultra-short treatment does not prevent subsequent cure of hepatitis ... High adherence and hepatitis C cure rates in active drug and alcohol users Keith Alcorn / 04 February 2021 People who use drugs achieved high rates of hepatitis C cure on direct-acting antiviral treatment despite ongoing drug and alcohol use, demonstrating that active drug use should not be a barrier to ... Simplified monitoring for hepatitis C is as effective as standard monitoring Keith Alcorn / 16 April 2019 People who had a simplified monitoring schedule of hepatitis C viral load tests at the beginning of treatment and 12 weeks after completing treatment were just as likely to be cured as ... Non-adherence most important risk factor for sofosbuvir/ledipasvir failure Keith Alcorn / 25 November 2016 Research carried out by Mount Sinai Medical Center, New York, found that non-adherence was the strongest risk factor for treatment failure in people taking sofosbuvir/ledipasvir (Harvoni). The main reasons cited for non-adherence ... A more personalised approach to hepatitis C treatment may improve adherence and completion rates Roger Pebody / 09 March 2015 People receiving treatment for hepatitis C value clinicians who give information and clinical feedback that is personalised to their individual needs and lifestyle, and cite this as an important facilitator of good adherence. ... Support improves hepatitis C treatment completion and response rates among drug users Michael Carter / 02 January 2013 Hepatitis C treatment completion and response rates among injecting drug users are similar to those seen in general patient populations, the findings of a meta-analysis published in the online edition of Clinical Infectious ... Adherence to hepatitis C treatment: unravelling the complexities Rob Camp / 13 December 2012 Successful adherence to hepatitis C treatment may require physicians and care teams to address a wide range of factors, according to research from the United States and Germany presented at The Liver Meeting ... Telaprevir twice-daily works as well as every eight hours, safe for hepatitis C patients with cirrhosis Liz Highleyman / 23 November 2012 The hepatitis C protease inhibitor telaprevir (Incivo or Incivek) taken twice daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved three-times-daily schedule, with similar safety ... Higher levels of adherence to hepatitis C therapy improve treatment outcomes in people with hepatitis C and HIV Michael Carter / 03 October 2012 Higher levels of adherence to pegylated interferon and ribavirin are associated with better hepatitis C treatment responses in people with HIV and hepatitis C co-infection, US investigators report in AIDS and Behavior. Adherence ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive